Phase II Trial of Fulvestrant with Metronomic Capecitabine for Postmenopausal Women with Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer.

TY - JOUR

T1 - Phase II Trial of Fulvestrant with Metronomic Capecitabine for Postmenopausal Women with Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer.

AU - Schwartzberg, Lee S.

AU - Wang, Grace

AU - Somer, Bradley G.

AU - Blakely, L. Johnetta

AU - Wheeler, Benton M.

AU - Walker, Mark S.

AU - Stepanski, Edward J.

AU - Houts, Arthur C.

N1 - Patients with ≤ 1 previous hormonal treatment in the metastatic setting received an injection fulvestrant loading dose 500 mg on day 1, 250 mg on days 15 and 29 followed by 250 mg every 28 days along with continuous oral capecitabine in divided doses.

PY - 2014/1/2

Y1 - 2014/1/2

UR - https://www.sciencedirect.com/science/article/pii/S1526820913002164

U2 - 10.1016/j.clbc.2013.09.003

DO - 10.1016/j.clbc.2013.09.003

M3 - Article

VL - 14

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

ER -